SURPASS-CVOT
2025
A Study of Tirzepatide Compared with Dulaglutide on Major Cardiovascular Events in Participants with Type 2 Diabetes
In 13,299 patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was non-inferior for major adverse cardiovascular events compared with dulaglutide (HR 0.92, 95.3% CI 0.83-1.01).
Result
Efficacy: Composite of CV death, myocardial infarction, or stroke (3-point MACE)HR 0.92 (95.3% CI 0.83-1.01) · P = 0.003
Below 1 favours tirzepatide, above 1 favours dulaglutide.
- Absolute difference
- 0.9 points
The absolute difference is derived from the event rates.
Also reported: Non-inferiority met but not superiority; all-cause mortality lower with tirzepatide.
- Subtopic
- GIP/GLP-1 RA
- Design
- Active-comparator-controlled, double-blind RCT, non-inferiority
- Relevance
- Supporting: context rather than must-know.
- Source
- Nicholls SJ, Pavo I, Bhatt DL, et al. N Engl J Med. 2025;393(24):2409-2420.doi 10.1056/NEJMoa2505928
Discussion & critique
Active comparator dulaglutide is itself cardioprotective, so non-inferiority does not establish benefit over placebo and MACE superiority was not met. Favourable metabolic, renal, and mortality signals support tirzepatide as at least as safe as an established GLP-1 agonist in ASCVD.